BEAM
Beam Therapeutics Inc.
Price Chart
Latest Quote
$29.43
+0.11 (+0.38%)
Current Price
| Previous Close | $29.32 |
| Open | $28.82 |
| Day High | $29.82 |
| Day Low | $28.33 |
| Volume | 1,307,692 |
Stock Information
| Shares Outstanding | 103.29M |
| Total Debt | $247.36M |
| Cash Equivalents | $1.15B |
| Revenue | $156.04M |
| Net Income | $-86.52M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $3.04B |
| EPS (TTM) | $-0.69 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $2.04B |
| Sales | $156.04M |
| Income | $-86.52M |
| Book/sh | $10.69 |
| Cash/sh | $11.16 |
| Employees | 540 |
Financial Ratios
| Quick Ratio | 14.25 |
| Current Ratio | 14.57 |
| Debt/Eq | 23.17 |
Returns & Margins
| ROA | -17.01% |
| ROE | -8.18% |
| Gross Margin | -161.91% |
| Operating Margin | -25827.14% |
| Profit Margin | -55.45% |
Ownership
| Insider Ownership | 1.37% |
| Institutional Ownership | 107.87% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -6.21 |
| P/S | 19.48 |
| P/B | 2.75 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $52.15 |
Technical Indicators
| SMA20 | $28.03 |
| SMA50 | $29.83 |
| SMA200 | $28.34 |
| RSI | 58.43 |
| ATR | 1.5774 |
| Shares Float | 88.24M |
| Short Float | 36.48% |
| Short Ratio | 13.28 |
| Volatility | 2.21 |
| Rel Volume | 0.78 |
Performance History
| Week | -1.11% |
| Month | +11.10% |
| Quarter | -10.63% |
| 6 Months | +3.41% |
| YTD | +8.44% |
| Year | +74.56% |
| 3 Years | +25.23% |
| 5 Years | -71.13% |
| 10 Years | +56.96% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-08-31 | $29.43 | 1,307,692 |
| 2026-08-27 | $30.48 | 1,268,800 |
| 2026-08-26 | $30.19 | 1,386,700 |
| 2026-08-25 | $31.03 | 2,187,300 |
| 2026-08-24 | $28.33 | 1,244,500 |
| 2026-08-21 | $29.76 | 2,457,300 |
| 2026-08-20 | $28.39 | 2,409,500 |
| 2026-08-19 | $29.07 | 3,111,300 |
| 2026-08-18 | $26.57 | 1,195,700 |
| 2026-08-17 | $27.10 | 1,470,200 |
| 2026-08-14 | $26.75 | 1,229,800 |
| 2026-08-13 | $26.51 | 2,021,800 |
| 2026-08-12 | $26.71 | 1,554,100 |
| 2026-08-11 | $26.85 | 1,329,400 |
| 2026-08-10 | $27.28 | 1,253,700 |
| 2026-08-07 | $27.48 | 1,324,200 |
| 2026-08-06 | $27.25 | 1,168,600 |
| 2026-08-05 | $27.07 | 2,056,900 |
| 2026-08-04 | $28.35 | 2,150,800 |
| 2026-08-03 | $25.91 | 1,295,000 |
About Beam Therapeutics Inc.
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a. The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs. In addition, it develops BEAM-103, an anti-CD117 monoclonal antibody that enables ESCAPE. The company has research collaboration agreement with Pfizer Inc., focusing on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Verve Therapeutics, Inc., for cardiovascular disease treatments; and Orbital Therapeutics to design RNA for the prevention, treatment, or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
đ° Latest News
Beam Therapeutics (BEAM) Stock May Look Stretched As Sales Expectations Climb
Simply Wall St. âĸ 2026-08-26T06:20:19Z
4 Gene-Editing Biotech Stocks Worth Watching for Long-Term Gains
Zacks âĸ 2026-08-24T13:59:00Z
BEAM's Q2 Loss Wider Than Expected, Revenues Fall Y/Y, Pipeline in Focus
Zacks âĸ 2026-08-05T15:10:00Z
Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Lags Revenue Estimates
Zacks âĸ 2026-08-04T12:25:02Z
Myriad Genetics (MYGN) Reports Q2 Loss, Misses Revenue Estimates
Zacks âĸ 2026-07-30T22:00:14Z
Scribeâs Genetic Editing Aims to Prevent Heart Attacks
Barrons.com âĸ 2026-07-30T14:26:00Z
Cathie Wood Is Buying This Up-and-Coming Biotech Stock. Should You Follow Her Lead?
Motley Fool âĸ 2026-07-20T17:50:00Z
Bank of America Securities Maintains Buy Rating for Beam Therapeutics (BEAM)
Insider Monkey âĸ 2026-07-15T14:01:53Z
Prime Medicine (PRME) Reaches Positive Resolution to Arbitration with Beam Therapeutics
Insider Monkey âĸ 2026-07-15T08:53:17Z
Kyverna Therapeutics Sinks 13%: Hereâs Why
24/7 Wall St. âĸ 2026-07-10T19:59:59Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $139,743,000 | $63,518,000 | $377,709,000 | $60,920,000 |
| Operating Revenue | $139,743,000 | $63,518,000 | $377,709,000 | $60,920,000 |
| Expenses | ||||
| Total Expenses | $523,436,000 | $479,086,000 | $554,194,000 | $399,399,000 |
| Other Income Expense | $259,968,000 | $-10,229,000 | $-1,352,000 | $63,004,000 |
| Net Non Operating Interest Income Expense | $43,733,000 | $49,094,000 | $46,676,000 | $15,297,000 |
| Total Other Finance Cost | $-43,733,000 | $-49,094,000 | $-46,676,000 | $-15,297,000 |
| Operating Expense | $523,436,000 | $479,086,000 | $554,194,000 | $399,399,000 |
| General And Administrative Expense | $113,818,000 | $111,525,000 | $116,813,000 | $87,805,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-79,992,000 | $-376,742,000 | $-132,527,000 | $-289,088,000 |
| Net Interest Income | $43,733,000 | $49,094,000 | $46,676,000 | $15,297,000 |
| Normalized Income | $-84,814,000 | $-366,513,000 | $-131,458,920 | $-338,861,160 |
| Net Income From Continuing And Discontinued Operation | $-79,992,000 | $-376,742,000 | $-132,527,000 | $-289,088,000 |
| Total Operating Income As Reported | $-383,693,000 | $-415,568,000 | $-176,485,000 | $-338,479,000 |
| Net Income Common Stockholders | $-79,992,000 | $-376,742,000 | $-132,527,000 | $-289,088,000 |
| Net Income | $-79,992,000 | $-376,742,000 | $-132,527,000 | $-289,088,000 |
| Net Income Including Noncontrolling Interests | $-79,992,000 | $-376,742,000 | $-132,527,000 | $-289,088,000 |
| Net Income Continuous Operations | $-79,992,000 | $-376,742,000 | $-132,527,000 | $-289,088,000 |
| Pretax Income | $-79,992,000 | $-376,703,000 | $-131,161,000 | $-260,178,000 |
| Special Income Charges | $180,000 | $1,592,000 | $9,740,000 | $18,904,000 |
| Earnings From Equity Interest | $255,146,000 | $0 | $0 | - |
| Operating Income | $-383,693,000 | $-415,568,000 | $-176,485,000 | $-338,479,000 |
| Earnings From Equity Interest Net Of Tax | - | $0 | $0 | $-25,500,000 |
| Per Share | ||||
| Diluted EPS | $-0.81 | $-4.58 | $-1.72 | $-4.13 |
| Basic EPS | $-0.81 | $-4.58 | $-1.72 | $-4.13 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $-283,920 | $13,230,840 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-366,221,000 | $-383,414,000 | $-155,121,000 | $-378,906,000 |
| Total Unusual Items | $4,822,000 | $-10,229,000 | $-1,352,000 | $63,004,000 |
| Total Unusual Items Excluding Goodwill | $4,822,000 | $-10,229,000 | $-1,352,000 | $63,004,000 |
| Reconciled Depreciation | $22,294,000 | $21,925,000 | $20,012,000 | $22,577,000 |
| EBITDA (Bullshit earnings) | $-361,399,000 | $-393,643,000 | $-156,473,000 | $-315,902,000 |
| EBIT | $-383,693,000 | $-415,568,000 | $-176,485,000 | $-338,479,000 |
| Diluted Average Shares | $98,905,577 | $82,313,008 | $77,151,771 | $70,015,305 |
| Basic Average Shares | $98,905,577 | $82,313,008 | $77,151,771 | $70,015,305 |
| Diluted NI Availto Com Stockholders | $-79,992,000 | $-376,742,000 | $-132,527,000 | $-289,088,000 |
| Tax Provision | $0 | $39,000 | $1,366,000 | $3,410,000 |
| Restructuring And Mergern Acquisition | $-180,000 | $-1,592,000 | $-9,740,000 | $-18,904,000 |
| Gain On Sale Of Security | $4,642,000 | $-11,821,000 | $-11,092,000 | $44,100,000 |
| Research And Development | $409,618,000 | $367,561,000 | $437,381,000 | $311,594,000 |
| Selling General And Administration | $113,818,000 | $111,525,000 | $116,813,000 | $87,805,000 |
| Other Gand A | $113,818,000 | $111,525,000 | $116,813,000 | $87,805,000 |
Fetched: 2026-08-12
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $1,238,358,000 | $733,545,000 | $981,329,000 | $733,474,000 |
| Total Assets | $1,481,177,000 | $1,103,824,000 | $1,459,714,000 | $1,341,714,000 |
| Total Non Current Assets | $212,489,000 | $225,675,000 | $248,671,000 | $248,818,000 |
| Other Non Current Assets | $7,310,000 | $9,398,000 | $10,865,000 | $14,685,000 |
| Current Assets | $1,268,688,000 | $878,149,000 | $1,211,043,000 | $1,092,896,000 |
| Other Current Assets | $23,478,000 | $27,409,000 | $21,167,000 | $14,762,000 |
| Cash Cash Equivalents And Short Term Investments | $1,245,210,000 | $850,740,000 | $1,189,876,000 | $1,078,134,000 |
| Cash And Cash Equivalents | $294,944,000 | $281,967,000 | $435,895,000 | $232,767,000 |
| Receivables | - | - | - | $0 |
| Accounts Receivable | - | - | - | $0 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $154,123,000 | $161,425,000 | $172,689,000 | $179,005,000 |
| Long Term Debt And Capital Lease Obligation | $139,759,000 | $147,956,000 | $159,911,000 | $168,625,000 |
| Current Debt And Capital Lease Obligation | $14,364,000 | $13,469,000 | $12,778,000 | $10,380,000 |
| Long Term Debt | - | - | - | - |
| Current Debt | - | - | - | - |
| Other Current Borrowings | - | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $242,819,000 | $370,279,000 | $478,385,000 | $608,240,000 |
| Total Non Current Liabilities Net Minority Interest | $145,884,000 | $188,213,000 | $272,820,000 | $384,645,000 |
| Other Non Current Liabilities | $6,125,000 | $1,635,000 | $3,021,000 | $13,841,000 |
| Derivative Product Liabilities | $0 | $5,404,000 | $0 | - |
| Non Current Deferred Liabilities | $0 | $33,218,000 | $109,888,000 | $202,179,000 |
| Current Liabilities | $96,935,000 | $182,066,000 | $205,565,000 | $223,595,000 |
| Other Current Liabilities | $12,399,000 | $16,211,000 | $39,441,000 | $30,562,000 |
| Current Deferred Liabilities | $6,659,000 | $108,858,000 | $68,706,000 | $135,974,000 |
| Payables And Accrued Expenses | $34,171,000 | $21,956,000 | $62,866,000 | $27,557,000 |
| Payables | $10,231,000 | $3,871,000 | $1,617,000 | $9,029,000 |
| Accounts Payable | $10,231,000 | $3,871,000 | $1,617,000 | $9,029,000 |
| Equity | ||||
| Common Stock Equity | $1,238,358,000 | $733,545,000 | $981,329,000 | $733,474,000 |
| Total Equity Gross Minority Interest | $1,238,358,000 | $733,545,000 | $981,329,000 | $733,474,000 |
| Stockholders Equity | $1,238,358,000 | $733,545,000 | $981,329,000 | $733,474,000 |
| Gains Losses Not Affecting Retained Earnings | $1,111,000 | $679,000 | $604,000 | $-2,430,000 |
| Other Equity Adjustments | $1,111,000 | $679,000 | $604,000 | $-2,430,000 |
| Retained Earnings | $-1,641,219,000 | $-1,566,631,000 | $-1,189,889,000 | $-1,057,362,000 |
| Other | ||||
| Ordinary Shares Number | $101,748,962 | $83,633,069 | $81,632,496 | $71,277,339 |
| Share Issued | $101,748,962 | $83,633,069 | $81,632,496 | $71,277,339 |
| Tangible Book Value | $1,238,358,000 | $733,545,000 | $981,329,000 | $733,474,000 |
| Invested Capital | $1,238,358,000 | $733,545,000 | $981,329,000 | $733,474,000 |
| Working Capital | $1,171,753,000 | $696,083,000 | $1,005,478,000 | $869,301,000 |
| Capital Lease Obligations | $154,123,000 | $161,425,000 | $172,689,000 | $179,005,000 |
| Total Capitalization | $1,238,358,000 | $733,545,000 | $981,329,000 | $733,474,000 |
| Additional Paid In Capital | $2,877,449,000 | $2,298,661,000 | $2,169,798,000 | $1,792,554,000 |
| Capital Stock | $1,017,000 | $836,000 | $816,000 | $712,000 |
| Common Stock | $1,017,000 | $836,000 | $816,000 | $712,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Non Current Deferred Revenue | $0 | $33,218,000 | $109,888,000 | $202,179,000 |
| Long Term Capital Lease Obligation | $139,759,000 | $147,956,000 | $159,911,000 | $168,625,000 |
| Current Deferred Revenue | $6,659,000 | $108,858,000 | $68,706,000 | $135,974,000 |
| Current Capital Lease Obligation | $14,364,000 | $13,469,000 | $12,778,000 | $10,380,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $29,342,000 | $21,572,000 | $21,774,000 | $19,122,000 |
| Current Accrued Expenses | $23,940,000 | $18,085,000 | $61,249,000 | $18,528,000 |
| Net PPE | $205,179,000 | $216,277,000 | $237,806,000 | $234,133,000 |
| Accumulated Depreciation | $-94,127,000 | $-72,107,000 | $-50,182,000 | $-30,170,000 |
| Gross PPE | $299,306,000 | $288,384,000 | $287,988,000 | $264,303,000 |
| Leases | $110,760,000 | $101,195,000 | $100,186,000 | $85,804,000 |
| Construction In Progress | $2,823,000 | $2,530,000 | $5,283,000 | $5,198,000 |
| Other Properties | $177,717,000 | $176,653,000 | $174,520,000 | $165,896,000 |
| Machinery Furniture Equipment | $8,006,000 | $8,006,000 | $7,999,000 | $7,405,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $950,266,000 | $568,773,000 | $753,981,000 | $845,367,000 |
| Buildings And Improvements | - | - | - | - |
Fetched: 2026-08-12
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-360,048,000 | $-356,192,000 | $-182,927,000 | $-26,424,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-345,102,000 | $-347,246,000 | $-149,195,000 | $22,527,000 |
| Cash Flow From Continuing Operating Activities | $-345,102,000 | $-347,246,000 | $-149,195,000 | $22,527,000 |
| Operating Gains Losses | $-255,447,000 | $-2,272,000 | $-7,500,000 | $1,600,000 |
| Investing Activities | ||||
| Capital Expenditure | $-14,946,000 | $-8,946,000 | $-33,732,000 | $-48,951,000 |
| Investing Cash Flow | $-121,438,000 | $185,007,000 | $71,840,000 | $-461,336,000 |
| Cash Flow From Continuing Investing Activities | $-121,438,000 | $185,007,000 | $71,840,000 | $-461,336,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $470,513,000 | $0 | $269,537,000 | $108,258,000 |
| Financing Cash Flow | $478,049,000 | $7,736,000 | $276,448,000 | $111,590,000 |
| Cash Flow From Continuing Financing Activities | $478,049,000 | $7,736,000 | $276,448,000 | $111,590,000 |
| Net Common Stock Issuance | $470,513,000 | $0 | $269,537,000 | $108,258,000 |
| Common Stock Issuance | $470,513,000 | $0 | $269,537,000 | $108,258,000 |
| Net Other Financing Charges | - | - | $-631,000 | $-188,000 |
| Net Preferred Stock Issuance | - | - | - | - |
| Preferred Stock Issuance | - | - | - | - |
| Other | ||||
| Repayment Of Debt | $0 | $-485,000 | $-2,252,000 | $-2,287,000 |
| Interest Paid Supplemental Data | $0 | $32,000 | $160,000 | $376,000 |
| End Cash Position | $301,620,000 | $290,111,000 | $444,614,000 | $245,521,000 |
| Beginning Cash Position | $290,111,000 | $444,614,000 | $245,521,000 | $572,740,000 |
| Changes In Cash | $11,509,000 | $-154,503,000 | $199,093,000 | $-327,219,000 |
| Proceeds From Stock Option Exercised | $7,536,000 | $8,221,000 | $9,163,000 | $5,807,000 |
| Net Issuance Payments Of Debt | $0 | $-485,000 | $-2,252,000 | $-2,287,000 |
| Net Long Term Debt Issuance | $0 | $-485,000 | $-2,252,000 | $-2,287,000 |
| Long Term Debt Payments | $0 | $-485,000 | $-2,252,000 | $-2,287,000 |
| Net Investment Purchase And Sale | $-361,560,000 | $193,953,000 | $105,572,000 | $-412,385,000 |
| Sale Of Investment | $848,232,000 | $680,392,000 | $1,089,910,000 | $1,204,614,000 |
| Purchase Of Investment | $-1,209,792,000 | $-486,439,000 | $-984,338,000 | $-1,616,999,000 |
| Net Business Purchase And Sale | $255,068,000 | $0 | $0 | $0 |
| Sale Of Business | $255,146,000 | $0 | $0 | $0 |
| Purchase Of Business | $-78,000 | $0 | $0 | - |
| Net PPE Purchase And Sale | $-14,946,000 | $-8,946,000 | $-33,732,000 | $-48,951,000 |
| Purchase Of PPE | $-14,946,000 | $-8,946,000 | $-33,732,000 | $-48,951,000 |
| Change In Working Capital | $-131,016,000 | $-110,223,000 | $-116,455,000 | $251,628,000 |
| Change In Other Working Capital | $-135,417,000 | $-36,518,000 | $-159,559,000 | $-35,920,000 |
| Change In Other Current Liabilities | $-13,835,000 | $-12,478,000 | $-10,362,000 | $9,861,000 |
| Change In Payables And Accrued Expense | $13,725,000 | $-55,878,000 | $60,085,000 | $-14,560,000 |
| Change In Accrued Expense | $7,685,000 | $-57,685,000 | $67,663,000 | $-16,933,000 |
| Change In Payable | $6,040,000 | $1,807,000 | $-7,578,000 | $2,373,000 |
| Change In Account Payable | $6,040,000 | $1,807,000 | $-7,578,000 | $2,373,000 |
| Change In Prepaid Assets | $4,511,000 | $-5,349,000 | $-6,619,000 | $-7,753,000 |
| Other Non Cash Items | $24,715,000 | $8,076,000 | $-221,000 | $-18,901,000 |
| Stock Based Compensation | $94,244,000 | $120,662,000 | $98,647,000 | $84,321,000 |
| Unrealized Gain Loss On Investment Securities | $-3,942,000 | $14,093,000 | $18,592,000 | $-20,200,000 |
| Amortization Of Securities | $-15,958,000 | $-22,765,000 | $-29,743,000 | $-9,410,000 |
| Depreciation Amortization Depletion | $22,294,000 | $21,925,000 | $20,012,000 | $22,577,000 |
| Depreciation And Amortization | $22,294,000 | $21,925,000 | $20,012,000 | $22,577,000 |
| Depreciation | $22,294,000 | $21,925,000 | $20,012,000 | $22,577,000 |
| Gain Loss On Investment Securities | $-301,000 | $-2,272,000 | $-7,500,000 | $-23,900,000 |
| Gain Loss On Sale Of Business | $-255,146,000 | $0 | $0 | - |
| Net Income From Continuing Operations | $-79,992,000 | $-376,742,000 | $-132,527,000 | $-289,088,000 |
| Change In Receivables | - | $0 | $-146,000 | $300,000,000 |
| Earnings Losses From Equity Investments | - | $0 | $0 | $25,500,000 |
| Change In Other Current Assets | - | - | $0 | $0 |
| Issuance Of Debt | - | - | - | $0 |
| Long Term Debt Issuance | - | - | - | $0 |
Fetched: 2026-08-12